Targeting diverse chimeric antigen receptor T cell-related targets in treatment of B-cell hematological malignancies:a review of long-term follow-up data
10.12307/2025.565
- VernacularTitle:不同嵌合抗原受体T细胞相关靶点治疗B细胞血液恶性肿瘤:长期随访数据综述
- Author:
Fanping XU
1
;
Qinchun LI
1
;
Dongfang TANG
1
Author Information
1. 湖南科技学院,湖南省永州市 425199
- Publication Type:Journal Article
- Keywords:
B cell hematological malignancies;
chimeric antigen receptor T cells;
immunotherapy;
therapeutic targets;
long-term efficacy;
toxic side effects;
recurrence
- From:
Chinese Journal of Tissue Engineering Research
2026;30(1):248-259
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Chimeric antigen receptor T cell therapy is a cutting-edge approach for the treatment of B cell hematological malignancies.These cells efficiently and specifically recognize and kill tumor cells,unrestricted by major histocompatibility complex limitations.OBJECTIVE:To elucidate the structure,developmental history,and marketed progress of chimeric antigen receptor T cells,summarize their long-term efficacy in B cell hematological malignancies treatments,and discuss associated toxicities,recurrence,and mitigation strategies.Additionally,it reviews the advancement of potential targets in B cell hematological malignancies treatments.METHODS:Searches were conducted in PubMed,CNKI,and WanFang databases using the terms"CAR-T,B cell hematological malignancies,toxic side effects,immunotherapy"in Chinese and English,focusing on articles regarding chimeric antigen receptor T cell targets in B-cell malignant tumor treatments.RESULTS AND CONCLUSION:(1)The U.S.Food and Drug Administration and National Medical Products Administration have approved 11 chimeric antigen receptor T cell products,primarily targeting CD19 and B cell maturation antigen targets in B cell hematological malignancies.(2)Long-term follow-up data indicate that chimeric antigen receptor T cell therapy provides a high remission rate and enduring responses in B cell hematological malignancies patients,albeit with recurrence issues due to antigen loss or downregulation.(3)Chimeric antigen receptor T cell therapy is associated with significant toxicities,a high recurrence rate,and drug resistance,constraining its broad application.(4)Future research should concentrate on developing new targets,combined therapies,and strategies to enhance chimeric antigen receptor T cell persistence and antitumor activity.
